Your browser doesn't support javascript.
loading
Response to Lisinopril in Patients with Sickle Cell Anemia and Proteinuria.
Aleem, Aamer; Al-Sultan, Abdulrahman; Alsuwaida, Abdulkareem; Alsaleh, Khalid; Algahtani, Farjah; Almomen, Abdulkareem; Sharif, Mohammad; Alotaibi, Ghazi S.
Afiliación
  • Aleem A; Department of Medicine, Oncology Center, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
  • Al-Sultan A; Department of Pediatrics, Oncology Center, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
  • Alsuwaida A; Department of Medicine, Division of Nephrology, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
  • Alsaleh K; Department of Medicine, Oncology Center, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
  • Algahtani F; Department of Medicine, Oncology Center, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
  • Almomen A; Department of Medicine, Oncology Center, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
  • Sharif M; Department of Medicine, Oncology Center, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
  • Alotaibi GS; Department of Medicine, Oncology Center, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
Saudi J Kidney Dis Transpl ; 34(6): 531-536, 2023 Nov 01.
Article en En | MEDLINE | ID: mdl-38725203
ABSTRACT
Proteinuria is a manifestation of sickle cell anemia (SCA)-related renal disease and is a risk factor of renal impairment. Angiotensin-converting enzyme (ACE) inhibitors have benefits, but their role in SCA remains undefined. This study aimed to assess the role of lisinopril, an ACE inhibitor, in reducing proteinuria in SCA patients. Thirty-five patients older than 15 years with known SCA (HbSS or HbS-ß0) and a 24-h urinary protein level of 150 mg or more participated in this study. Urine was collected over 24 h to quantify proteinuria. The patients had a mean age of 28.5 ± 6.98 years. The median 24-h urinary protein before treatment was 0.3006 g and that after treatment was 0.150 g (P = 0.01). After a median follow-up of 38 months, 24-h urinary protein decreased in 27 (77%) patients and normalized in 18 (52%) patients. Urinary protein increased in 2 (6%) patients and remained stable (no change) in 6 (17%) patients. There was no significant difference in blood pressure (BP) before and after treatment. The average dose of lisinopril was 5 mg. Twenty patients were still on lisinopril at last follow-up. The reasons for stopping lisinopril included normalization of protein, noncompliance, adverse effects, and pregnancy. Lisinopril effectively reduced proteinuria in SCA patients, without significantly reducing BP. Only a few patients developed adverse effects, including coughing, dizziness, and diarrhea. It is unclear how long lisinopril should be continued and whether it can be stopped in patients with normalized urinary protein.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteinuria / Inhibidores de la Enzima Convertidora de Angiotensina / Lisinopril / Anemia de Células Falciformes Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Saudi J Kidney Dis Transpl Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteinuria / Inhibidores de la Enzima Convertidora de Angiotensina / Lisinopril / Anemia de Células Falciformes Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Saudi J Kidney Dis Transpl Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita
...